Published November 2016, following VacZine Analytics' attendance at IDweek2016 in New Orleans (October 26-30). Hospital vaccine pipeline intelligence is available in VAMV070 (A. baumannii) and VAMV064 (ExPEC).
The Scale of the AMR Crisis
Antimicrobial resistance is an 'urgent' health crisis. A 2013 CDC report estimated that approximately 23,000 deaths and at least 2 million illnesses occur each year in the United States as a direct result of AMR. These numbers compound further when Clostridium difficile infection (CDI) is included: CDI hospitalises at least 250,000 people per year with an estimated 14,000 deaths. From a cost perspective, AMR costs the US economy $20bn in excess direct medical costs and $35bn in lost productivity.
The problem is not confined to the United States. A 2014 report predicted that deaths due to all AMR - then running at 700,000 per year - would reach 10 million per year by 2050. The scale prompted the United Nations to hold a high-level meeting on AMR in 2016, only the fourth time in the body's 70-year history that it had convened on a health-related issue.
Annual US deaths directly attributable to antimicrobial resistance. At least 2 million Americans develop AMR-related infections each year, costing the economy an estimated $55bn in direct and indirect costs.
The 2017 Joint Commission Standard
To combat inappropriate antimicrobial use, the US Joint Commission announced a new Medication Management standard (MM.09.01.01) for hospitals, critical access hospitals, and nursing care centres wishing to participate in Medicare and Medicaid. The standard, addressing antimicrobial stewardship, became effective January 1, 2017. Healthcare providers must now establish detailed protocols using a multidisciplinary stewardship team including an infectious disease physician, infection preventionist, pharmacist, and practitioner.
Many attendees at IDweek2016 conference workshops admitted their institution was not fully ready for the 2017 programme. The new standard requires coordinated analysis of electronic health records, surveillance systems (EPIC, TheraDoc), and tracking of antibiotic prescribing and resistance patterns. The associated rapid diagnostic technologies - PCR, nucleic acid methods, MALDI-TOF - promise earlier organism identification and improved antimicrobial stewardship, but involve equipment costs of hundreds of thousands of dollars that must pass the scrutiny of budget-conscious hospital committees.
The Financial Stakes for Hospitals
Since 2008, US hospitals have been penalised under Medicare's value-based purchasing programme if patients acquire any of eight infection-related conditions. In 2017, the rules tightened further: MRSA infections were added to Medicare's Hospital Value-Based Purchasing scorecard, with their weighting increased from 65% to 85%. With hospital profit margins in the low single digits, adoption of all available infection prevention measures is now a business necessity.
"With hospital profit margins in the low single digits, it is highly critical that all available measures are adopted to reduce healthcare-associated infections. It is now a business necessity."
The Case for Nosocomial Vaccines
Is antimicrobial stewardship alone sufficient? Probably not. The advancement of new antibiotics appears only incremental, with a marked increase in cost. For several years, the industry has grappled with the concept of a 'nosocomial' vaccine - administered prior to patient risk exposure - to protect vulnerable patients and reduce reliance on antibiotics. There have been notable high-profile failures: NABI's StaphVAX, the Merck/Intercell IsdB, and Valneva's P. aeruginosa vaccine VLA43. However, Sanofi Pasteur's Clostridium difficile vaccine was in late-stage Phase III at the time of this article, followed by Pfizer's multi-antigen S. aureus vaccine SA4Ag in Phase IIb. The direction of travel in hospital infection prevention creates a compelling case for vaccine development to continue.
This article is available in VacZine Analytics' Expert News archive as published in November 2016. VacZine Analytics attended IDweek2016 in New Orleans, Louisiana, October 26-30, 2016.